Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about " Overall Response Rate"

Bristol Myers Squibb Reports Positive Phase 2 Results for Arlo-cel in Relapsed/Refractory Multiple Myeloma

$Bristol Myers Squibb Reports Positive Phase 2 Results for Arlo-cel in Relapsed/Refractory Multiple Myeloma$

Bristol Myers Squibb’s arlo-cel demonstrated statistically significant and clinically meaningful responses in patients with quadruple-class exposed relapsed and refractory multiple myeloma.

Overall Response Rate | 09/09/2026 | By News Bureau

BioInvent's BI-1808 Receives FDA Fast Track Designation for Ovarian Cancer

BioInvent’s BI-1808 has received FDA Fast Track Designation for ovarian cancer, supporting accelerated development of the investigational anti-TNFR2 therapy in combination with pembrolizumab.

Overall Response Rate | 11/08/2026 | By News Bureau

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members